<?xml version="1.0" encoding="UTF-8"?>
<p>On the contrary, many research laboratories and companies are continuing their activities, as before the implementation of community legislation, under the umbrella of the hospital exemption. Countries that have been fully harmonized with the Regulation EU/1394/2007 are seeking approval by the national competent body. Thus, in Germany nine “products” have national permits, eight as well as in Poland, the UK 18 ATMP are in production under the Article 5 (1) of Directive 2001/83/EC; while for other countries there is no information available [
 <xref rid="R11" ref-type="bibr">11</xref>]. At the same time more than 900 clinical trials involving ATMP are in progress, most of them in phase I/II. The key players in the development and delivery of ATMP remain academic/research centers and small and medium-sized enterprises [
 <xref rid="R08" ref-type="bibr">8</xref>, 
 <xref rid="R12" ref-type="bibr">12</xref>], while the involvement of pharmaceutical companies is focusing on recent developments in the treatment of oncological incidents with 
 <italic>in vitro</italic> modified cytotoxic T lymphocytes and chimeric antigen receptor (CAR)-T cells [
 <xref rid="R13" ref-type="bibr">13</xref>].
</p>
